Evogene (EVGN)
(Delayed Data from NSDQ)
$0.62 USD
+0.02 (3.18%)
Updated Jul 22, 2024 11:09 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EVGN 0.62 +0.02(3.18%)
Will EVGN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EVGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EVGN
Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
EVGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
Here's Why Evogene (EVGN) is a Great Momentum Stock to Buy
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
Other News for EVGN
ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants
EverGen Infrastructure Announces Record RNG Production at Fraser Valley Biogas in June 2024
Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat
Evogene transferred with Buy rating at Alliance Global Partners
Lake Street Remains a Buy on Evogene (EVGN)